Singapore markets closed

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7001+0.0535 (+8.27%)
At close: 04:00PM EDT
0.6900 -0.01 (-1.44%)
After hours: 07:56PM EDT

Veru Inc.

2916 North Miami Avenue
Suite 1000
Miami, FL 33127
United States
305 509 6897
https://verupharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees189

Key executives

NameTitlePayExercisedYear born
Dr. Mitchell S. Steiner F.A.C.S., M.D.Chairman, President & CEO885.32kN/A1961
Dr. Harry Fisch F.A.C.S., M.D.Vice Chairman & Chief Corporate OfficerN/AN/A1959
Ms. Michele GrecoCFO & Chief Administrative Officer493.7kN/A1959
Dr. K. Gary Barnette Ph.D.Chief Scientific Officer676.27kN/A1968
Mr. Samuel FischExecutive Director of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Michael J. PurvisExecutive VP, General Counsel & Corporate Strategy and SecretaryN/AN/AN/A
Mr. Kevin J. Gilbert CPA, J.D.Executive Vice President of Corporate DevelopmentN/AN/AN/A
Mr. Martin TaylerExecutive Vice President of FC2 Global Operations180.51kN/A1969
Mr. Philip R. Greenberg J.D.Executive VP & Deputy General CounselN/AN/AN/A
Dr. Domingo Rodriguez M.D.Executive Vice President of Global Clinical OperationsN/AN/A1962
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Corporate governance

Veru Inc.’s ISS governance QualityScore as of 1 March 2024 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.